Arjuna
Best-in-class: Arjuna
An Ayurvedic cardiac tonic with a small but non-trivial trial base in heart failure and angina.
Arjuna quick facts
| Suggested dose | 500 mg one to three times daily. |
| How often | Daily |
| Who it's for | Adjunct cardiac support under medical supervision. |
Small trials in angina and heart failure are encouraging but mostly Indian, small, and of variable methodological quality. Mechanistically plausible and under-investigated rather than disproven. Same principle as hawthorn — anything with a cardiac mechanism belongs in a monitored context, not as a self-directed substitute for treatment.
How Arjuna actually works
Terminalia arjuna bark contains arjunolic acid and related triterpenes, with proposed antioxidant, mild inotropic and coronary vasodilator effects. Traditional Ayurvedic use for cardiac complaints goes back centuries; the modern mechanistic account remains less precisely defined than hawthorn's.
Where to get Arjuna
Find Arjuna on iHerb →The evidence for Arjuna
Graded by what exists behind each claim.
✅ Clinically validated
- Small randomized trials report improved left ventricular ejection fraction and reduced angina frequency. Studies are small and largely regional.
📊 Correlative data
- Centuries of traditional use specifically as a heart remedy.
🧪 Theoretical / extrapolated benefits
- Proposed inotropic and antioxidant effects on cardiac tissue.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Arjuna actually does
Start with what arjuna is not, because the commonest explanation given for it is wrong. Terminalia arjuna bark is not a cardiac glycoside plant. It contains no digoxin-like compound, it does not inhibit the sodium-potassium ATPase the way foxglove does, and any description of it as a natural digitalis is chemistry that was never done. What the bark actually carries is a triterpenoid family — arjunolic acid, arjunic acid, arjungenin and their glycosides — together with a substantial load of hydrolysable tannins and flavonoids Dwivedi 2014.
So what is the target? The honest answer is that no molecular target has been established in a human, and the most interesting fact on this page is that the best-designed trial went looking and found something other than the expected thing. One hundred patients with chronic heart failure took the water extract for 12 weeks; ejection fraction did not change (24.3 ± 7.1% against 25.5 ± 7.7%, p = 0.4), but red-cell catalase activity was preserved against placebo (p = 0.01) Maulik 2016. Catalase is the enzyme that converts hydrogen peroxide to water and oxygen; the failing heart runs at high oxidative flux and consumes its antioxidant enzyme capacity. That result points at a redox-buffering mechanism rather than an inotropic one, and the two make completely different predictions.
The inotropic claim and what would have to be true for it. The 1995 study in refractory heart failure reported ejection fraction rising from 30.24 ± 7.13% to 35.33 ± 7.85% (p < 0.005) with left ventricular volumes falling Bharani 1995. If that is real inotropy, it has to run through calcium: either more calcium entering per beat, more released from the sarcoplasmic reticulum through the ryanodine receptor, or greater myofilament calcium sensitivity, which is the levosimendan route and the only one of the three that does not cost extra oxygen. Nobody has measured any of them for this plant. That is not a small gap — it is the difference between a drug that helps a failing heart and one that drives it harder.
The angina result implies a fourth mechanism entirely. Fifty-eight men with chronic stable angina got 500 mg eight-hourly, and angina episodes fell from 18.22 ± 9.29 to 5.69 ± 6.91 per week with treadmill time rising from 4.76 ± 2.38 to 6.14 ± 2.51 minutes (p < 0.005) Bharani 2002. Angina is a supply-demand mismatch, and the comparator in that trial was isosorbide mononitrate — a venodilator that works by reducing preload. If arjuna matches a nitrate, the parsimonious explanation is that it is doing something similar to loading conditions, which is a vascular claim, not a myocardial one.
And a fifth: the lipid and inflammatory arm. In 116 patients with stable coronary disease taking 500 mg twice daily for six months, triglycerides and VLDL cholesterol fell along with immuno-inflammatory markers Kapoor 2015. Tannin-rich bark extracts plausibly act in the gut lumen on lipid absorption, which would be a mechanism with no cardiac component at all.
Five candidate mechanisms, five different organs, and no experiment that separates them. That is the actual state of this plant, and it is more interesting than the tidy version.
Cell, rodent, human — and where it stops
In cells and rodents. Arjunolic acid on cardiomyocyte lines and in isoproterenol- or doxorubicin-injured rat myocardium, oral or intraperitoneal, days to weeks, reading lipid peroxidation, endogenous antioxidant enzymes and infarct size Dwivedi 2014. The rodent models are chemical-injury models, and chemical-injury protection is the easiest thing in cardiology to demonstrate and the hardest to translate.
In people, and the trial base is small but real. Twelve patients with NYHA class IV refractory congestive heart failure took 500 mg of bark extract eight-hourly against placebo for two weeks each in a blinded crossover, followed by an open phase of 20–28 months; ejection fraction rose and left ventricular end-diastolic volume index fell from 134.56 ± 29.71 to 125.28 ± 27.91 ml/m² (p < 0.005) Bharani 1995. Fifty-eight men with stable angina crossed over between arjuna, isosorbide mononitrate 40 mg daily and placebo for one week each Bharani 2002. One hundred and sixteen patients with stable coronary artery disease took 500 mg twice daily for six months Kapoor 2015. And one hundred patients with NYHA class II heart failure and an ejection fraction of 40% or less took 750 mg twice daily for 12 weeks Maulik 2016.
The obstacle is that the trials get bigger and the effect gets smaller. Twelve people, positive on ejection fraction Bharani 1995. Fifty-eight people, positive on angina Bharani 2002. One hundred people, double-blind, randomized, negative on ejection fraction Maulik 2016. That is the classic shape of an effect that was partly artefact of small samples and unblinded follow-up — and it is also compatible with a real but different effect that the later trial measured correctly. Both readings are defensible; what is not defensible is quoting the 1995 ejection-fraction number without the 2016 one.
Two more obstacles worth naming. First, the angina crossover gave each arm one week Bharani 2002, which is long enough to read a nitrate-like effect and far too short to read anything structural. Second, the entire trial base is regional and mostly single-center, which is exactly the setting in which a positive literature is hardest to replicate elsewhere.
And the doses differ by 50%. 500 mg three times daily in the early trials Bharani 1995Bharani 2002, 500 mg twice daily in the CAD trial Kapoor 2015, 750 mg twice daily in the negative heart-failure trial Maulik 2016. The negative trial used the highest daily dose, which removes underdosing as the explanation for its result.
Arjuna — which form, and does it matter
Bark, and specifically stem bark, and specifically an extract. The trial materials are bark extracts — the negative heart-failure trial names a water extract of the stem bark Maulik 2016. Water, ethanol and hydroalcoholic extracts pull different fractions from this plant: the triterpenoid glycosides and the hydrolysable tannins have very different solubilities, so an aqueous decoction and a 50% ethanolic extract are chemically different products sold under one name.
No standardization marker is agreed, and that is unusual for a plant this well studied. There is no consensus number of the sort that ruscogenin gives butcher's broom or that flavanones give bergamot. Some products quote total tannins, some quote arjunolic acid, most quote nothing. Without a marker, 500 mg of one bottle and 500 mg of another are the same weight of two different chemistries, and the trials cannot be mapped onto either.
Powdered bark churna is the traditional form and is not the trial form. Ayurvedic practice uses arjuna bark powder in gram quantities, frequently decocted in milk. The trials used extract capsules at 500–750 mg Bharani 1995Maulik 2016. Substituting one gram of raw powder for one 500 mg extract capsule is a dose change of unknown size and direction.
Dosing interval carries an inference worth stating. The two positive trials dosed every eight hours Bharani 1995Bharani 2002; the negative one dosed twice daily Maulik 2016. If the active has a short half-life — which triterpenoid glycosides and tannin metabolites generally do — then three-times-daily and twice-daily are not the same regimen even at a higher total dose, and the trough matters. That is a labeled extrapolation and it is the single most testable difference between the trials that worked and the trial that did not.
What would have to be true, and how you would know it was not
Read this section with the warning attached: heart failure and angina are cardiology, and the predictions below are for somebody already under a cardiologist, not instead of one.
1. Angina episode count down by half within two weeks, or not at all. The angina trial ran one week per arm and produced a fall from 18.22 to 5.69 episodes per week Bharani 2002. A nitrate-like loading effect appears fast; a structural effect does not. So the prediction is sharp: if arjuna is acting the way that trial suggests, a diary of episodes per week will show it inside 14 days. Nothing by four weeks means this mechanism is not operating in you.
2. Triglycerides down, and this is the softest target with the best odds. Six months at 500 mg twice daily lowered triglycerides and VLDL cholesterol in stable coronary disease Kapoor 2015. Predict a 10–20% fall in fasting triglycerides at 12 weeks in someone starting above 150 mg/dL, and essentially nothing in someone already at 80 mg/dL. Triglycerides swing with the last two days of eating, so this one needs a genuine 12-hour fast and preferably two baseline draws.
3. hs-CRP down at three to six months. The inflammatory markers moved over six months, not weeks Kapoor 2015. Predict hs-CRP falls by 0.5–1.5 mg/L from a starting value above 2 mg/L, and predict it is slower than the lipid change — a different biology on a different clock.
4. The prediction that cuts against the product, and it is already published. Ejection fraction will not move. The largest and best-designed trial gave a higher dose for longer than the positive studies and found 24.3% against 25.5%, p = 0.4 Maulik 2016. Predict a repeat echocardiogram at six months shows nothing outside the ±5% measurement error of the technique. If you are buying arjuna to raise an ejection fraction, the best evidence says you will not see it, and the echo will cost more than the supplement.
What will fool you: heart-failure symptoms fluctuate enormously with salt intake, sleep and infection. A good fortnight is not a treatment effect. And this is the one page in this cohort where the placebo response has real teeth — exercise tolerance is effort-dependent and effort is expectation-dependent.
What nobody has tested yet
The dosing-interval experiment is the obvious one and nobody has run it. Three times daily at 500 mg produced positive results Bharani 1995Bharani 2002; twice daily at 750 mg did not Maulik 2016. A three-arm trial at matched total daily dose, split two ways versus three ways versus placebo, with six-minute walk distance as the endpoint, would settle whether the difference is pharmacokinetic or whether the early results simply did not replicate.
Nobody has measured NT-proBNP in an arjuna trial. It is the standard objective marker of ventricular wall stress, it moves within weeks, it is far more sensitive than an ejection fraction read off an echocardiogram by eye, and it is a single blood tube. Its absence from a heart-failure literature this old is remarkable Maulik 2016.
The catalase finding has never been followed up. Preserved red-cell catalase activity against placebo at p = 0.01 in a trial that was negative on its primary endpoint Maulik 2016 is either a chance finding among several measured or the actual mechanism of the plant. Repeating it as a pre-specified primary endpoint, with myocardial rather than erythrocyte readouts if possible, is a small trial that would tell you which.
And nobody has run arjuna against a nitrate with a modern endpoint. The 2002 comparison against isosorbide mononitrate Bharani 2002 used episode counts and treadmill time in a one-week crossover. Repeating it with quantitative myocardial perfusion imaging would say whether arjuna improves supply, reduces demand, or simply changes how the chest feels — three answers with different consequences for whether it should be used at all.
Arjuna — its own safety story, not its category's
This has genuine cardiac and vascular activity, and that is the risk, not an inert-herb reassurance. A substance that changes ejection fraction, angina frequency and exercise tolerance Bharani 1995Bharani 2002 is by definition capable of interacting with the drugs that do the same. Beta-blockers, antihypertensives, nitrates and antiarrhythmics all belong in that sentence, and the direction of the interaction is additive, so the signal to watch for is hypotension and bradycardia, not treatment failure.
The thyroid signal, stated precisely enough to test. This site's own card warns that arjuna may affect thyroid hormone levels, and the rodent reports behind that warning describe a fall in T3 with a rise or no change in T4 — which is the fingerprint of inhibited peripheral 5'-deiodination rather than a thyroid-gland effect. That distinction is testable and it matters: gland-level suppression would move TSH, while deiodinase inhibition would leave TSH relatively undisturbed and drop free T3 alone. If you take arjuna and you are on levothyroxine, ask for free T3 as well as TSH and free T4 at three months, because a TSH-only panel is exactly the panel that would miss this.
Never as a substitute, and the reason is outcome data. Angiotensin-converting enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors have mortality data in heart failure. Arjuna has 12 patients, 58 patients, 116 patients and one negative trial of 100 Bharani 1995Bharani 2002Kapoor 2015Maulik 2016. Stopping a drug with a survival curve to take a bark extract with a symptom score is the single most dangerous thing anybody could do with this page.
Tannin load, which is the boring risk and the likeliest one to bite. Arjuna bark is tannin-rich Dwivedi 2014. At 1.5 g a day of extract that is a substantial daily dose of hydrolysable tannin, which chelates non-heme iron in the gut lumen and causes constipation and gastric discomfort. Heart-failure patients are frequently anemic and frequently constipated already. Separate it from iron by two hours and recheck ferritin at six months.
Antiplatelet activity is plausible and unmeasured. Treat the two-week pre-surgical stop as the default, and say it out loud to the anesthetist, who will ask about warfarin and not about bark.
Sources read for this page
- Bharani A, et al. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.. International Journal of Cardiology 1995 · PMID 7649665
- Bharani A, et al. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate.. Indian Heart Journal 2002 · PMID 12086380
- Maulik SK, et al. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial.. Phytomedicine 2016 · PMID 26988798
- Kapoor D, et al. Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence.. Journal of Cardiovascular Translational Research 2015 · PMID 25827448
- Dwivedi S, et al. Revisiting Terminalia arjuna - An Ancient Cardiovascular Drug.. Journal of Traditional and Complementary Medicine 2014 · PMID 25379463
How you would know if it worked
Neither of these numbers tells you whether this works, and that is the point. Whatever an Ayurvedic cardiac tonic does to a heart is settled by an echocardiogram and an angina diary held by the cardiologist you are already under — ejection fraction is not a blood test, the trials reporting it are small and largely regional, and a supplement page should say so rather than name a marker to look thorough. What a draw is genuinely for here is the interaction this product's own entry flags: arjuna has been reported to affect thyroid hormone levels, and thyroid disease both imitates and worsens cardiac symptoms — an unnoticed shift in TSH would look exactly like the heart problem you are treating. Draw it before you start and again 6-8 weeks in, and take the result to the prescriber, not to the internet.
- TSH (Thyroid-Stimulating Hormone) Retest: 6–8 weeks after any dose change; annually if stable.
- Free T4 (Thyroxine) Retest: 6–8 weeks after any dose change.
The cheapest panel carrying TSH (Thyroid-Stimulating Hormone) and at least one other of these is Thyroid — First Look, at $22 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Arjuna — safety & side effects
- GI upset, headache and mild constipation.
- Has genuine cardiac activity — additive with antihypertensives, beta-blockers and antiarrhythmics. May affect thyroid hormone levels.
- Mild antiplatelet activity. Heart failure and angina need cardiology, not a botanical alone. Not established as safe in pregnancy or breastfeeding — not because harm is documented, but because these are the two populations systematically excluded from the trials. Absence of data is not reassurance.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Arjuna in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Arjuna
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| ApoB (Apolipoprotein B) | Counts the particles that cause plaque — a normal LDL-C can hide risk |
| Lipoprotein(a) — Lp(a) | Genetic, largely unmodifiable, and worth knowing once in your life |
| hs-CRP (High-Sensitivity C-Reactive Protein) | The inflammatory half of cardiovascular risk |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | The standard baseline these are usually aimed at |
The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
Arjuna — frequently asked questions
What is Arjuna?
An Ayurvedic cardiac tonic with a small but non-trivial trial base in heart failure and angina.
What is the suggested dose of Arjuna?
500 mg one to three times daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Arjuna dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Arjuna?
Coach Cam sources Arjuna from vetted, top-rated brands on iHerb — use the buy link on this page.
What Arjuna is used for
Arjuna appears under 1 goal in the goal router.
Related Cardiovascular supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.